

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A07/2017 OS

DESPATCHED ON 18TH JULY 2017

HLA PHENOTYPE OF BLOOD DONOR: A1, A3; B7, B44; Cw4, Cw7; DR7, DR15; DQ2, DQ6

Summary of Results																	
PBL				T-Cells				B-Cells									
Total tested	12	13	13	13	31	34	29	34	31	31	27	31					
Positive	8	1	8	0	19	0	15	0	30	25	22	0					
Negative	4	12	5	13	12	34	14	34	1	6	5	31					
NT/Equivocal	3	2	2	2	7	4	9	4	8	8	12	8					
% Positive	66.7%	7.7%	61.5%	0.0%	61.3%	0.0%	51.7%	0.0%	96.8%	80.6%	81.5%	0.0%					
% Negative	33.3%	92.3%	38.5%	100.0%	38.7%	100.0%	48.3%	100.0%	3.2%	19.4%	18.5%	100.0%					
Consensus	Not Assessed	Negative	Not Assessed	Negative	Not Assessed	Negative	Not Assessed	Negative	Positive	Positive	Positive	Negative					
HLA Antibody Specificity (Defined By CDC)	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3					
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Without DTT				Without DTT				Without DTT				Comments	
	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4					
101		YES	YES						Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
112	YES			NT	NT	NT	NT										Low cell viability
114		YES	YES						Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
116		YES	YES						Positive	Negative	Positive	Negative	Equivocal	Equivocal	Equivocal	Equivocal	Sample delivery was delayed and the viability of B cells was too low for the test
119	YES			Positive	Negative	Positive	Negative										
120		YES	YES						Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
128	YES			Negative	Negative	Negative	Negative										
133		YES	YES						NT	NT	NT	NT					Cell viability too low
139	YES	YES	YES	Equivocal	Negative	Negative	Negative	Equivocal	Equivocal	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
143		YES	YES						Positive	Negative	Negative	Negative					Serum 1 without DTT is reported as weakly positive
145		YES	YES						Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
147	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
154		YES	YES						Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
157		YES	YES						Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
159		YES	YES						Negative	Negative	Equivocal	Negative	Positive	Positive	Equivocal	Negative	
162		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
163		YES	YES						Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
169		YES	YES						Positive	Negative	Equivocal	Negative	Positive	Positive	Positive	Negative	
181		YES	YES						Equivocal	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
186		YES	YES						Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
189	YES			Negative	Negative	Negative	Negative										
190		YES	YES						Negative	Negative	Positive	Negative	Positive	Positive	Positive	Negative	The number of B cells is low
193	YES	YES	YES	Positive	Negative	Positive	Negative	Positive	Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
194		YES	YES						Negative	Negative	Equivocal	Negative	Positive	Positive	Equivocal	Negative	
195		YES	YES						Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
197		YES	YES						Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
204		YES	YES						Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
206		YES	YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT	B cells NT because viability < 50%
209	YES			Positive	Negative	Positive	Negative						NT	NT	NT	NT	
216	YES			Positive	Negative	Positive	Negative										
223		YES	YES						Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
227		YES	YES						Negative	Negative	NT	Negative					Serum 3: Failure technique
229	YES																
232	YES			Positive	Negative	Positive	Negative										
235	YES			Positive	Negative	Positive	Negative										
238	YES	YES	YES	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Positive	Positive	Positive	Negative	
239	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Viability of negative controls were found highly positive. Samples can not be finalized.
245	YES	YES	YES	Positive	Positive	Positive	Negative	Positive	Negative	Positive	Positive	Negative	Positive	Positive	Positive	Negative	
252	YES	YES	YES	Negative	Negative	Negative	Negative										
259	YES																
260		YES	YES						NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability
268		YES	YES						Positive	Negative	Positive	Negative	Positive	Positive	Positive	Negative	
284		YES	YES						Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
292		YES	YES						Negative	Negative	Negative	Negative	Positive	Negative	Equivocal	Negative	As cell viability was low, we reported equivocal for B cells serum 3.
293		YES	YES						Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	
294		YES	YES						Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
297		YES	YES						Equivocal	Negative	Equivocal	Negative	Positive	Positive	Positive	Negative	
321		YES	YES						Positive	Negative	Positive	Negative	NT	NT	NT	NT	Insufficient number of B-cells
351		YES	YES						NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A07/2017 OS

DESPATCHED ON 18TH JULY 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101					-	-	-	-	-	-	-	-			
112	NT	NT	NT	NT									45		
114					4	1	1	1	8	8	4	1			
116					6	1	4-6	1	Equivocal	Equivocal	Equivocal	Equivocal	95	60	
119	4	1	2	1									90		
120					4	1	4	1	8	8	4	1		99	99
128	1	1	1	1									98		
133					NT	NT	NT	NT	NT	NT	NT	NT	50	50	40
139	Equivocal	1	1	1	Equivocal	1	1	1	8	8	8	1	85	85	85
143					4	1	1	1					87		
145					2-4	-	-	-	2-4	-	-	-	100	100	
147	2	1	1	1	2	1	1	1	8	8	2	1	100	100	90
154					2	-	-	-	4	4	6	-	10		
157					1	1	1	1	4	1	1	1	90		
159					1	1	2	1	8	8	2	1		99	90
162					-	-	-	-	-	-	-	-		100	100
163					6	1	8	1	8	8	8	1		80	80
169					6	1	Equivocal	1	8	8	8	1		97	97
181					2/4	1	4	1	8	8	6	1		100	100
186					4	0	2	0	8	8	6	0		99	99
189	1	1	1	1									95		
190					5	5	40	5	100	95	95	10		95	95
193	++	-	++	-	++	-	++	-	++++	++++	++	-	95	95	95
194					-	-	Equivocal	-	-	-	Equivocal	-			
195					2	2	2	2	6	6	6	2		80	70
197					-	-	-	-	Weak	-	-	-		70	80
204					4	1	4	1	8	8	6	1		95	90
206					1	1	1	1	NT	NT	NT	NT		100	
209	2	1	2	1					NT	NT	NT	NT			
216	4	2	4	2									90		
223					6	1	8	1	8	6	6	2		95	95
227					2	-	NT	-	8	6	NT	-		98	98
229															
232	6+	-	6+	-									80		
235	4	1	4	1									85		
238	4	1	6	1	4	1	6	1	8	6	8	1	98	98	50
239	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	40	40	40
245	4	2	6	1	4	1	4	1	6	6	4	1	100	100	100
252	2	1	2	1					8	8	6	1		80	70
259															
260					NT	NT	NT	NT	NT	NT	NT	NT		30	30
268					4	1	8	1	4	2	2	1		92	86
284					1	1	2	1	8	8	8	1		98	90
292					1	1	1	1	4	1	2	1		60	30
293					2+	0	6+	0	8+	0	8+	0		80	50
294					4	0	2	0	8	8	8	0		95	50
297					2-4	1	2-4	1	8	8	8	1		80	80
321					2	1	6	1	NT	NT	NT	NT		98	
351															

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A07/2017 OS

DESPATCHED ON 18TH JULY 2017

HLA PHENOTYPE OF BLOOD DONOR: A1, A3; B7, B44; Cw4, Cw7; DR7, DR15; DQ2, DQ6

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	11	12	12	12	29	31	30	31	29	29	25	29				
Positive	6	1	2	0	12	0	1	0	28	23	5	0				
Negative	5	11	10	12	17	31	29	31	1	6	20	29				
NT/Equivocal	2	1	1	1	5	3	4	3	7	7	11	7				
% Positive	54.5%	8.3%	16.7%	0.0%	41.4%	0.0%	3.3%	0.0%	96.6%	79.3%	20.0%	0.0%				
% Negative	45.5%	91.7%	83.3%	100.0%	58.6%	100.0%	96.7%	100.0%	3.4%	20.7%	80.0%	100.0%				
Consensus	Not Assessed	Negative	Negative	Negative	Not Assessed	Negative	Negative	Negative	Positive	Positive	Negative	Negative				
HLA Antibody Specificity (Defined By CDC)	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
101	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
112	YES	YES	YES	NT	NT	NT	NT	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	Low cell viability
114	YES	YES	YES	NT	NT	NT	NT	Positive	Negative	Negative	Negative	Equivocal	Equivocal	Equivocal	Equivocal	Sample delivery was delayed and the viability of B cells was too low for the test
116	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
119	YES	YES	YES	Equivocal	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Cell viability too low
120	YES	YES	YES	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
133	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
139	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
143	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
147	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
157	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
159	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
162	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
163	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
169	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
181	YES	YES	YES	Equivocal	Negative	Negative	Negative	Equivocal	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
186	YES	YES	YES	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Positive	Negative	Negative	
189	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	The number of B cells is low
190	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
193	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
194	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Equivocal	Negative	
195	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Equivocal	Negative	
197	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
204	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
206	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B cells NT because viability < 50%
209	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	NT	NT	NT	NT	
216	YES	YES	YES	Positive	Negative	Positive	Negative	Positive	Negative	Positive	Negative	NT	NT	NT	NT	
227	YES	YES	YES	Negative	Negative	NT	Negative	Negative	Negative	NT	Negative	Positive	Positive	NT	Negative	Serum 3: Failure technique
229	YES	YES	YES	Positive	Negative	Positive	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
235	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
238	YES	YES	YES	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Positive	Negative	Negative	
245	YES	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
252	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
260	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability
262	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Equivocal	Negative	
268	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
284	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
292	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
293	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
294	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
297	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
321	YES	YES	YES	Positive	Negative	Negative	Negative	Positive	Negative	Negative	Negative	NT	NT	NT	NT	Insufficient number of B-cells
351	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Low cell viability

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A07/2017 OS

DESPATCHED ON 18TH JULY 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101															
112	NT	NT	NT	NT	-	-	-	-	-	-	-	-	45		
114					4	1	1	1	8	8	4	1			
116					4	1	1	1	Equivocal	Equivocal	Equivocal	Equivocal	95	60	
119	1	1	1	1									90		
120					1	1	1	1	8	8	1	1		99	99
133					NT	NT	NT	NT	NT	NT	NT	NT	50	50	40
139	Equivocal	1	1	1	Equivocal	1	1	1	8	8	4	1	85	85	85
143					1	1	1	1						87	
147	2	1	1	1	2	1	1	1	8	8	1	1	100	100	90
157									4	1	1	1	90		
159					1	1	1	1	8	8	1	1		99	90
162					-	-	-	-	-	-	-	-		100	100
163					6	1	1	1	8	8	1	1		80	80
169					2	1	1	1	8	8	8	1		97	97
181					2/4	1	1	1	8	8	1	1		100	100
186					2	0	2	0	8	8	0	0		99	99
189	1	1	1	1									95		
190					5	5	5	5	100	100	10	10		95	95
193	++	-	-	-	+	-	-	-	++++	++++	-	-	95	95	95
194					-	-	-	-	-	-	Equivocal	-			
195					2	2	2	2	6	6	4	2		80	70
197					-	-	-	-	Weak	-	-	-		70	80
204					4	1	1	1	8	8	2	1		95	90
206					1	1	1	1	NT	NT	NT	NT		100	
209	2	1	1	1					NT	NT	NT	NT			
216	4	2	4	2									90		
227					2	-	NT	-	8	8	NT	-		98	98
229															
235	4	1	4	1									85		
238	4	1	1	1	4	1	1	1	8	6	1	1	98	98	50
245	4	2	1	1	4	1	1	1	6	6	1	1	100	100	100
252	2	1	2	1					8	8	6	1	80		70
260					NT	NT	NT	NT	NT	NT	NT	NT		30	30
262	1	1	1	1	1	1	1	1	6	8	4	1	100	100	100
268					4	1	1	1	4	4	1	1		92	86
284					1	1	1	1	8	8	8	1		98	90
292					1	1	1	1	4	1	1	1		60	30
293					2+	0	0	0	8+	0	0	0		80	50
294					0	0	0	0	4	2	0	0		95	50
297					1	1	1	1	8	8	1	1		80	80
321					2	1	1	1	NT	NT	NT	NT		98	
351															